Skip to content Skip to footer
Subscribe Now
NEWS

Santhera Pharmaceuticals Reports Swissmedic’s Approval of Agamree (Vamorolone) to Treat Duchenne Muscular Dystrophy

Shots: Swissmedic has approved Agamree for the treatment of pts (≥4yrs) with Duchenne muscular dystrophy and expects launch in H2’26 Approval was based on pivotal P-IIb (VISION-DMD) data and EMA assessments, granting 15-year Swiss orphan drug exclusivity; Santhera retains exclusive Swiss distribution. Trial met its 1EP of Time to Stand (TTSTAND) velocity vs PBO at…
January 15, 2026

Read more

VIEWPOINTS_David Domzalski_2024
VIEWPOINTS

Funds Raised: David Domzalski Discusses the Closing of VYNE Therapeutics’ Private Placement

Shots:  David Domzalski, President & Chief Executive Officer at VYNE Therapeutics, in an invigorating conversation with PharmaShots  The PIPE transaction generated $88M ensuring a steady cash flow through the end of 2025 and multiple anticipated clinical catalysts across VYNE’s BET inhibitor platform  David believes the financing will be instrumental in the advancement of VYN201, into…
January 29, 2024

Read more